255 related articles for article (PubMed ID: 24033530)
1. Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.
Moten MA; Gaber AO; Putney D; Patel SJ
Clin Transplant; 2013; 27(6):852-7. PubMed ID: 24033530
[TBL] [Abstract][Full Text] [Related]
2. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Ramos-Esquivel A; Salazar-Sánchez L
Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
4. Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.
Singer JP; Huang MY; Hui C; Blanc PD; Boettger RF; Golden J; Watkins K; Hoopes C; Leard LE
J Heart Lung Transplant; 2010 Sep; 29(9):1009-13. PubMed ID: 20627627
[TBL] [Abstract][Full Text] [Related]
5. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
6. Dosage of enoxaparin among obese and renal impairment patients.
Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
[TBL] [Abstract][Full Text] [Related]
7. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW; Lee JJ
Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Lim W; Dentali F; Eikelboom JW; Crowther MA
Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
[TBL] [Abstract][Full Text] [Related]
9. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
10. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
[TBL] [Abstract][Full Text] [Related]
11. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
12. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
13. Dosing low molecular weight heparins in kidney disease.
Saltiel M
J Pharm Pract; 2010 Jun; 23(3):205-9. PubMed ID: 21507815
[TBL] [Abstract][Full Text] [Related]
14. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
Rojas L; Aizman A; Ernst D; Acuña MP; Moya P; Mellado R; Cerda J
Thromb Res; 2013; 132(6):761-4. PubMed ID: 24521789
[TBL] [Abstract][Full Text] [Related]
15. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
16. Variability of plasma anti-Xa activities with different lots of enoxaparin.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
[TBL] [Abstract][Full Text] [Related]
17. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
18. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
19. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
Kopelman TR; O'Neill PJ; Pieri PG; Salomone JP; Hall ST; Quan A; Wells JR; Pressman MS
Am J Surg; 2013 Dec; 206(6):911-5; discussion 915-6. PubMed ID: 24296098
[TBL] [Abstract][Full Text] [Related]
20. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Lin H; Faraklas I; Saffle J; Cochran A
J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
